There is some evidence that haloperidol is an effective treatment for  acute mania .
From the limited data available , there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone .
Some evidence suggests that haloperidol could be less effective than aripiprazole .
BACKGROUND The main objectives in treating mania are to control dangerous behaviour , reduce suicide , produce appropriate acute sedation and shorten the episode of mood disturbance .
Among different drugs , haloperidol has for many years been used in treating psychotic patients , but it has a troublesome side effect profile .
OBJECTIVES To assess the effects of haloperidol for the treatment of mania in comparison with placebo or other active drugs , either as monotherapy or add-on treatment .
The Safety and Pharmacokinetics of Quetiapine When Coadministered With Haloperidol, Risperidone, or Thioridazine
The effects of haloperidol , risperidone , and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia , schizoaffective disorder , or bipolar disorder in a single-center , two-period , multiple-dose , open-label , r and omized trial . Over a one-to two-week period , quetiapine doses were escalated to 300 mg twice daily ( bid ) . Patients were then treated for at least 7 days at the target quetiapine dose and subsequently entered into the combination therapy period , receiving haloperidol ( 7.5 mg , bid ) , risperidone ( 3 mg , bid ) , or thioridazine ( 200 mg , bid ) for 8.5 days ( after 3 days of dose escalation ) . Key assessment s included the pharmacokinetics of quetiapine at steady state ( area under the curve within a dosing interval [ AUCtSS ] , maximum [ CmaxSS ] , and minimum [ CminSS ] observed plasma concentrations , and oral clearance [ Cl/f ] ) , as well as the UKU Side Effect Rating Scale scores and safety evaluations . Neither risperidone nor haloperidol had significant effects on quetiapine pharmacokinetics . However , thioridazine produced statistically significant changes , decreasing the least squares means values of the AUCtSS , CmaxSS , and CminSS by 40 % , 47 % , and 31 % , respectively , and increasing Cl/f by 68 % . Increases in the following adverse events were noted during coadministration : somnolence  ( risperidone )  , insomnia and dry mouth ( all three coadministered therapies ) , and dizziness  ( thioridazine ) . UKU side effect items that became worse in ≥ 25 % of patients during each coadministration period included sedation and increased sleep duration . Results of laboratory tests , electrocardiograms , and vital sign measurements revealed few clinical ly important changes . Clinical stability can be maintained with good tolerability during the transition from quetiapine monotherapy to periods of coadministration with haloperidol , risperidone , or thioridazine . Coadministration of either haloperidol or risperidone did not have any important effects on the steady-state pharmacokinetics of quetiapine . Thioridazine significantly increased the oral clearance of quetiapine . Increased doses of quetiapine may be necessary to control psychotic symptoms when thioridazine is coadministered with quetiapine
There is some evidence that haloperidol is an effective treatment for  acute mania .
From the limited data available , there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone .
Some evidence suggests that haloperidol could be less effective than aripiprazole .
BACKGROUND The main objectives in treating mania are to control dangerous behaviour , reduce suicide , produce appropriate acute sedation and shorten the episode of mood disturbance .
Among different drugs , haloperidol has for many years been used in treating psychotic patients , but it has a troublesome side effect profile .
OBJECTIVES To assess the effects of haloperidol for the treatment of mania in comparison with placebo or other active drugs , either as monotherapy or add-on treatment .